Takeda Continues To Shed Pipeline Assets In Roivant Deal
This article was originally published in PharmAsia News
Executive Summary
Takeda has set up a new company with Roivant to expedite the development of relugolix, an oral GnRH antagonist, for indications including prostate cancer and endometriosis.